靶向血脑屏障开放促进脑胶质母细胞瘤的多柔比星/抗 PD-1 化学免疫治疗。
Targeted opening of the blood-brain barrier facilitates doxorubicin/anti-PD-1-based chemoimmunotherapy of glioblastoma.
机构信息
Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université de Paris Cité, Sorbonne Université, Inserm U1138, Institut Universitaire de France, Paris, France.
Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif, France.
出版信息
Oncoimmunology. 2024 Jul 27;13(1):2385124. doi: 10.1080/2162402X.2024.2385124. eCollection 2024.
Doxorubicin is a prototypical inducer of immunogenic cell death (ICD) that sensitizes to subsequent immunotherapy by PD-1 blockade. However, this systemic drug combination fails against glioblastoma, hidden behind the blood-brain barrier (BBB). A recent work delineates a biophysical method for BBB permeabilization that yields effective preclinical effects of chemoimmunotherapy.
多柔比星是一种典型的免疫原性细胞死亡（ICD）诱导剂，通过 PD-1 阻断可增强对后续免疫治疗的敏感性。然而，这种全身药物联合治疗在血脑屏障（BBB）的阻碍下，对胶质母细胞瘤无效。最近的一项工作描述了一种用于 BBB 通透性的生物物理方法，该方法可产生有效的化疗免疫治疗的临床前效果。
Zotero 插件